9 Points To Consider For PS-341 That You Can Use Now

This study had 94% power to detect a confirmed response rate http://www.selleck.cn/products/bgj398-nvp-bgj398.html of 60%, with a 0.11 level of significance. For this age cohort, we planned to accrue a total of 46 evaluable patients. If at least 23 of all 46 evaluable patients had a confirmed response, this would be considered adequate evidence of promising activity and would warrant further testing of this regimen in subsequent studies. A similar 1-stage design was used for patients aged 70 and older. This study had 79% power to detect a confirmed response rate of 60%, with a 0.11 level of significance. For this age cohort, we planned to accrue a total of 24 evaluable patients. If at least 13 of all 24 evaluable patients had a confirmed response, this would be considered adequate evidence of promising activity and would warrant further testing of this regimen in subsequent studies. Secondary endpoints included toxicities, duration of response, time-to-disease progression, and overall http://www.selleckchem.com/products/Bortezomib.html survival. These endpoints were analyzed between the age groups (aged http://www.selleckchem.com/products/gsk1120212-jtp-74057.html multiple comparisons. Statistical analyses were performed using SAS software (SAS institute, Cary, NC). Between April 5, 2006 and September 14, 2007, 50 patients were enrolled in this study. Two patients were deemed ineligible (1 had received prior chemotherapy, and the other had a performance status of 3), and 2 other patients canceled before receiving any treatment, leaving a total of 46 evaluable patients (from 24 treatment locations) who were included in this analysis. The patients were analyzed in 2 age cohorts,